The estimated Net Worth of Mark Simon is at least 114 千$ dollars as of 18 October 2022. Mr. Simon owns over 125,000 units of Cabaletta Bio Inc stock worth over 29,820$ and over the last 5 years he sold CABA stock worth over 0$. In addition, he makes 83,822$ as Independent Director at Cabaletta Bio Inc.
Sign up
Mr. Simon CABA stock SEC Form 4 insiders trading
Mark has made over 1 trades of the Cabaletta Bio Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 125,000 units of CABA stock worth 122,500$ on 18 October 2022.
The largest trade he's ever made was buying 125,000 units of Cabaletta Bio Inc stock on 18 October 2022 worth over 122,500$. On average, Mark trades about 20,833 units every 0 days since 2019. As of 18 October 2022 he still owns at least 7,000 units of Cabaletta Bio Inc stock.
You can see the complete history of Mr. Simon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Simon biography
Mark J. Simon serves as Independent Director of the Company. He is a partner and co-founder of Torreya Partners, LLC, a global investment banking firm serving companies in the life sciences industry. Prior to co-founding Torreya, Mr. Simon was a managing director and head of life sciences investment banking at Citigroup from 2002 to 2005, and a senior biotechnology research analyst at Robertson Stephens from 1989 to 2002. He began his career at Kidder Peabody. Mr. Simon serves on the board of directors of Sun Pharma Advanced Research Company Limited. He received his MBA from Harvard Business School and his B.A. from Columbia College.
What is the salary of Mark Simon?
As the Independent Director of Cabaletta Bio Inc, the total compensation of Mark Simon at Cabaletta Bio Inc is 83,822$. There are 9 executives at Cabaletta Bio Inc getting paid more, with Anup Marda having the highest compensation of 1,528,630$.
How old is Mark Simon?
Mark Simon is 58, he's been the Independent Director of Cabaletta Bio Inc since 2018. There are 4 older and 9 younger executives at Cabaletta Bio Inc. The oldest executive at Cabaletta Bio Inc is Richard Henriques, 64, who is the Independent Director.
What's Mark Simon's mailing address?
Mark's mailing address filed with the SEC is C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA, 19104.
Insiders trading at Cabaletta Bio Inc
Over the last 5 years, insiders at Cabaletta Bio Inc have traded over 19,324,000$ worth of Cabaletta Bio Inc stock and bought 1,500,545 units worth 13,043,398$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Ventures V, L.P.5 Am Opport...、James E Deerfield Mgmt Iv, .... On average, Cabaletta Bio Inc executives and independent directors trade stock every 70 days with the average trade being worth of 632,329$. The most recent stock trade was executed by Gwendolyn Binder on 19 January 2024, trading 11,000 units of CABA stock currently worth 11,110$.
What does Cabaletta Bio Inc do?
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un
What does Cabaletta Bio Inc's logo look like?
Complete history of Mr. Simon stock trades at Cabaletta Bio Inc
Cabaletta Bio Inc executives and stock owners
Cabaletta Bio Inc executives and other stock owners filed with the SEC include:
-
Anup Marda,
Chief Financial Officer -
Steven Nichtberger,
Chairman of the Board, President, Chief Executive Officer, Co-Founder -
Gwendolyn Binder-Scholl,
Executive Vice President, Science & Technology -
Dr. Steven A. Nichtberger M.D.,
Co-Founder, Chairman, CEO & Pres -
Dr. Steven A. Nichtberger,
Co-Founder, Chairman, CEO & Pres -
Dr. David J. Chang M.D., M.P.H.,
Chief Medical Officer -
Dr. Gwendolyn K. Binder,
Exec. VP of Science & Technology -
Richard Henriques,
Independent Director -
Catherine Bollard,
Independent Director -
Mark Simon,
Independent Director -
Brian Daniels,
Independent Director -
David Chang,
Chief Medical Officer -
J. Brian Stalter,
General Counsel -
Michael Gerard J.D.,
Gen. Counsel & Sec. -
Heather Harte-Hall M.Sc.,
Chief Compliance Officer -
Michael Gerard,
Gen. Counsel -
Dr. Samik Basu M.D.,
Chief Scientific Officer -
Martha O'Connor,
Chief HR Officer -
J. Brian Stalter J.D.,
Gen. Counsel -
Dr. Aimee Payne M.D., Ph.D.,
Co-Founder & Co-Chair of Scientific Advisory Board -
Dr. Michael C. Milone M.D., Ph.D.,
Co-Founder & Co-Chair of Scientific Advisory Board -
Anup Marda M.B.A.,
Chief Financial Officer -
Shawn Tomasello,
-
Scott C. Brun,
-
Gwendolyn Binder,
See Remarks -
Arun Das,
Chief Business Officer -
Group, Llc Green Jeremy Red...,
-
James E Deerfield Mgmt Iv, ...,
-
Ventures V, L.P.5 Am Opport...,
-
Michael Gerard,
General Counsel